Health and Healthcare

Amgen : AMGN

All Amgen Articles

699 Articles

Trey Thoelcke | Dec 18, 2015 at 7:10 AM EST

4 Top Biotech Stocks for 2016

Biotech looks set to close out 2015 as its worst performing year since 2008. But can we expect a better…

Jon C. Ogg | Dec 15, 2015 at 4:52 PM EST

How Amgen’s Larger-Than-Expected Dividend Hike Stacks Up to Peers

Amgen is getting aggressive enough on its dividend payout that you might think the biotech giant is now just a…

Chris Lange | Dec 10, 2015 at 8:40 AM EST

Mixed Views on Major Biotech Short Interest

The November 30 short interest data have been compared with the previous report, and short interest was mixed in these…

Chris Lange | Nov 25, 2015 at 9:06 AM EST

Short Sellers Run for Cover From Major Biotechs

24/7 Wall St. has reviewed the short interest data on the top biotech companies.

Chris Lange | Nov 11, 2015 at 7:45 AM EST

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the October 30 settlement date, and short interest fell in selected biotech stocks.

Chris Lange | Oct 28, 2015 at 4:41 PM EDT

Amgen Beats Earnings With Solid Outlook For 2015

ThinkstockAmgen Inc. (NASDAQ: AMGN) released its third quarter earnings report Wednesday after the markets closed. The biotech giant had $2.72…

Chris Lange | Oct 28, 2015 at 11:25 AM EDT

What to Expect From Amgen Earnings

Amgen is scheduled to report its third-quarter financial results after the markets close on Wednesday.

Chris Lange | Oct 27, 2015 at 8:10 AM EDT

Short Sellers Become More Selective on Leading Biotechs

The October 15 short interest data have been compared with the previous figures, and short interest mixed in these selected…

Chris Lange | Oct 23, 2015 at 1:35 PM EDT

Why Amgen’s Future Is Looking Bright

Amgen is slowly getting closer to an FDA final decision for its first-of-a-kind cancer therapy, talimogene laherparepvec (T-Vec).

Lee Jackson | Oct 20, 2015 at 10:05 AM EDT

Q3 Worst for Biotech in 7 Years: Which Large Cap Leaders to Buy Now

Cowen says the way to play biotech is with large cap sector leaders that can beat earnings estimates. It also…

Chris Lange | Oct 12, 2015 at 8:20 AM EDT

Short Sellers Increase Bets in Major Biotechs

The September 30 short interest data have been compared with the previous figures, and short interest increased in most of…

Lee Jackson | Oct 9, 2015 at 10:05 AM EDT

UBS Loves These 3 Top Biotech Stock Leaders Into Q3 Earnings

Given the massive beat-down in the sector, if these companies surpass earnings expectations, the upside could be sizable.

Jon C. Ogg | Sep 29, 2015 at 11:25 AM EDT

Independent Research Sees 3 Top Health and Biotech Stocks as Oversold

Independent research firm Argus has reviews of three of health care picks from its own Focus List in which it…

Chris Lange | Sep 26, 2015 at 9:25 AM EDT

How the Top Biotechs Handled the Valuation Shock

24/7 Wall St. has taken a look at some of the largest biotech companies and highlighted the damage that a…

Chris Lange | Sep 25, 2015 at 8:05 AM EDT

Short Sellers Increase Bets in Major Biotech

The September 15 short interest data have been compared with the previous figures, and short interest in these selected stocks…

1 … 23 24 25 26 27 … 47

Amgen : AMGN

All Amgen Articles

4 Top Biotech Stocks for 2016

How Amgen’s Larger-Than-Expected Dividend Hike Stacks Up to Peers

Mixed Views on Major Biotech Short Interest

Short Sellers Run for Cover From Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Amgen Beats Earnings With Solid Outlook For 2015

What to Expect From Amgen Earnings

Short Sellers Become More Selective on Leading Biotechs

Why Amgen’s Future Is Looking Bright

Q3 Worst for Biotech in 7 Years: Which Large Cap Leaders to Buy Now

Short Sellers Increase Bets in Major Biotechs

UBS Loves These 3 Top Biotech Stock Leaders Into Q3 Earnings

Independent Research Sees 3 Top Health and Biotech Stocks as Oversold

How the Top Biotechs Handled the Valuation Shock

Short Sellers Increase Bets in Major Biotech

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Amgen : AMGN

All Amgen Articles

4 Top Biotech Stocks for 2016

How Amgen’s Larger-Than-Expected Dividend Hike Stacks Up to Peers

Mixed Views on Major Biotech Short Interest

Short Sellers Run for Cover From Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Amgen Beats Earnings With Solid Outlook For 2015

What to Expect From Amgen Earnings

Short Sellers Become More Selective on Leading Biotechs

Why Amgen’s Future Is Looking Bright

Q3 Worst for Biotech in 7 Years: Which Large Cap Leaders to Buy Now

Short Sellers Increase Bets in Major Biotechs

UBS Loves These 3 Top Biotech Stock Leaders Into Q3 Earnings

Independent Research Sees 3 Top Health and Biotech Stocks as Oversold

How the Top Biotechs Handled the Valuation Shock

Short Sellers Increase Bets in Major Biotech

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

Featured Reads

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%